Pathways for Pulmonary Delivery

Summary: New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small molecules and systemic indications. Nebulizer and dry power inhaler modalities are growing and driving demand for specialized CDMOs like Catalent, who can provide the end-to-end solutions, scientific knowledge, and the scalable manufacturing capabilities necessary to meet the needs of inhalation innovators and accelerate time to market.